SYNAPS Dx (SDx) is observing November as National Alzheimer’s Disease Awareness Month to support those directly impacted by Alzheimer’s disease and shares the importance of an early and accurate Alzheimer’s diagnosis. November also marks National Family Caregivers Month, which honors those who actively care for family members who require at-home care, including those who suffer from Alzheimer’s.
In the United States, over 11 million people provide unpaid care for those with AD or other dementias with over 80% of care for older Americans being provided by family, friends and other unpaid caregivers and nearly half of this care is for people with AD or another type of dementia.
This November, join SDx in raising awareness of the importance of an early diagnosis of Alzheimer’s to alleviate worry for older Americans and their families and get them on the optimal therapeutic journey earlier in their disease.
The Difficulty in Diagnosing Alzheimer’s
A growing number of aging adults lead experts to predict there will be 13 million people with Alzheimer’s disease by 2050, with symptoms of dementia being difficult to differentiate from typical age-related behavior changes and other common and potentially curable conditions.
Physicians have found great difficulty in diagnosing AD, with 50% to 70% of symptomatic AD patients not correctly diagnosed in primary care and 25% to 30% misdiagnosed in specialized memory clinics. Additionally, 1/3 of older adults reported delaying care in 2021, while 1/5 of this population experienced negative impacts from delayed care.
How DISCERN Can Help
Understanding that there are many causes of dementia, SDx developed the DISCERN™ test, the first and only autopsy-validated skin test, to provide healthcare professionals with a diagnostic tool to accurately identify AD in people suffering from dementia symptoms, even in the presence of mixed-dementia. A minimally invasive, routine 3mm skin punch biopsy, DISCERN can be administered in the clinician’s office and is paid for by Medicare.
* The DISCERN™ test was developed and its performance characteristics determined by NeuroDiagnostics Inc, dba Synaps Dx. It has not been cleared or approved by the U.S. Food and Drug Administration. NeuroDiagnostics, Inc. is regulated under the Clinical Laboratory Improvement Amendments (CLIA) as an accredited laboratory to perform high complexity clinical testing. The test is intended for patients with dementia. Test results should be interpreted in conjunction with other laboratory and clinical data available to the clinician. All rights reserved.